Paul L. Berns

Paul L. Berns

Chief Executive OfficeratNeumora Therapeutics· In proxies 2022–2025

Pay in FY2025-47% from the year before · Neumora Therapeutics stock -83.1% the same year

Paul L. Berns was paid $4.6M in FY2025 (Dec), down 47%. Neumora Therapeutics stock fell 83.1% that year.

Pay$100 in the stock at the end of FY23 → $10
Pay is from the Summary Compensation Table of each Neumora Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Neumora TherapeuticsPublic company · 4 yr
    • Chief Executive Officer2022 – Present · 4 yrStock in role -98%
  2. HI BioPublic company · 7 yr
    • Director2019 – Present · 7 yrNo stock prices for these years
  3. NICO TherapeuticsPublic company · 7 yr
    • Director2019 – Present · 7 yrNo stock prices for these years
  4. EpiriumPublic company
    • Director? – PresentNo stock prices for these years
  5. Happy AIPublic company
    • Director? – PresentNo stock prices for these years
  6. KardiganPublic company
    • Director? – PresentNo stock prices for these years
  7. Mirador TherapeuticsPublic company
    • Director? – PresentNo stock prices for these years
  8. RhygazePublic company
    • Director? – PresentNo stock prices for these years
  9. Salma HealthPublic company
    • Director? – PresentNo stock prices for these years
  10. Jazz Pharmaceuticals, PLCPublic company
    • Director? – PresentNo stock prices for these years
  11. MC2 TherapeuticsPublic company
    • Director? – PresentNo stock prices for these years
  12. Menlo TherapeuticsPublic company
    • Director? – PresentNo stock prices for these years
  13. Metsera, Inc.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?